OPN和RANKL在中耳胆脂瘤中的表达

Expressions of osteopontin and receptor activator of nuclear factor-kappa B ligand in middle ear cholesteatoma

目的探讨骨桥蛋白(OPN)和核因子κB受体性活化因子配体(RANKL)在中耳胆脂瘤组织中的表达。方法采用免疫组织化学EnVision二步法检测OPN和RANKL在35例中耳胆脂瘤上皮(A组)、25例肉芽组织(B组)和20例正常外耳道上皮(C组)中的表达。结果 A组和B组OPN和RANKL的表达高于C组[(0.1746±0.0326和0.1606±0.0244vs.0.0148±0.0024)和(0.1562±0.0346和0.1246±0.0264vs.0.0134±0.0021)](P<0.05)。在A组和B组中,OPN与RANKL的表达均呈正相关(r=0.3902和r=0.5178,P<0.05)。结论 OPN和RANKL与中耳胆脂瘤骨质破坏存在正向协同作用。

Objective To study the expressions of osteopontin（OPN） and receptor activator of nuclear factor-kappa B ligand （RANKL） in human middle ear cholesteatoma. Methods The expressions of OPN and RANKL were detected by immunohistochemical EnVision method in 35 cases with middle ear cholesteatoma specimens（group A）, 25 cases with granulation tissues surrounding the cholesteatoma（group B） and 20 specimens of normal external ear canal skin（group C）. Results The positive expressions of OPN and RANKL were higher in groups of A and B than those in group C [-（0. 1746±0. 0326 and 0. 1606±0. 0244 vs. 0. 0148±0. 0024） and （0. 1562±0. 0346 and 0. 1246± 0. 0264 vs. 0. 0134±0. 0021）3（P〈0. 05）. The expression of OPN was positively correlated to that of RANKL in groups of A and B（r=0. 3902 and r=0. 5178,P〈0. 05）. Conclusion The expressions of OPN and RANKL have a positive synergistic effect in bone destruction of middle ear cholesteatoma.